Innovation

A new foundation for future talent

We’re partnering with N.C. A&T to launch a collaborative biotechnology learning center

April 22, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Building the workforce of tomorrow means investing in the students of today. That’s why we’ve partnered with North Carolina Agricultural and Technical State University (N.C. A&T) — the largest historically Black college and university in the U.S. — to launch the Merck Biotechnology Learning Center.

“We’re pleased to launch this new collaboration with an institution that precisely aligns to our company priorities to invest in the growth and delivery of innovative health solutions and strong values around diversity and inclusion,” said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. “Together we can fuel the growth of talent for our company and the biotechnology industry overall.”

Located in the home state of our Durham and Wilson manufacturing sites, the 4,025 square-foot facility will enhance academic programming and training for biotechnology careers for N.C. A&T students and provide advanced discovery opportunities through its classroom space, process laboratory and state-of-the-art biopharmaceutical manufacturing equipment.

“This collaboration signifies a union between academia and industry, and a commitment to excellence, innovation and the advancement of scientific knowledge,” said Tonya Smith-Jackson, Ph.D., provost and executive vice chancellor of academic affairs for N.C. A&T.

The collaboration also signifies an investment in the community’s future by expanding local and statewide bioeconomy initiatives. It’ll also help to expand talent and recruitment opportunities for our company and offer vaccine manufacturing process training for new and existing employees. 

“The Merck Biotechnology Learning Center will provide opportunities for N.C. A&T students to look inside the biopharmaceutical industry and understand what a career in this space looks like. Through our joint initiative with N.C. A&T, we’re developing new and innovative ways to build a pipeline of talent here in North Carolina and beyond.” 

  • Amanda Taylor
    Vice president and Durham plant manager
Innovation

Humans, animals and the environment – our health is all connected

Why the One Health approach is important now more than ever

April 15, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

little girl hugging a white dog

The health of humans, animals and the environment are all interconnected. When the health of one is at risk, the health of all may be at risk.   

We see it in diseases transferred between animals or insects and humans (called zoonotic and vector-borne diseases) such as rabies, Lyme disease, West Nile virus, swine flu and Ebola, among others. We also see it in the growing threat from antimicrobial resistance (AMR), which occurs when bacteria mutate in ways that make the medicines (antimicrobials) used to treat infections ineffective, or when these medicines are used inappropriately to treat viral infections. Or, in diseases in food-producing animals, jeopardizing global food security.

Our increasing vulnerability to such new health challenges has led to a focus on “One Health” — an integrated approach to addressing human, animal and environmental health for the benefit of all.

What is One Health?

One Health is the collaborative approach across multiple disciplines — working locally, regionally, nationally and globally — to prevent, detect and respond to health issues at the interfaces between humans, animals and the environment.

illustration of lots of people working together

It requires collaboration among doctors, veterinarians, nurses, public health practitioners, epidemiologists, agricultural workers, ecologists, wildlife experts, and industry as well as policymakers, communities and even pet owners.

“No one person, organization or sector can address these issues alone. Identifying and responding to growing health challenges requires teamwork,” says Holger Lehmann, DVM, Ph.D., VP, pharmaceuticals research and development, Merck Animal Health.

But what has led to these increasing population health threats?

Why are we more vulnerable to new health challenges?

Society has undergone major changes over the past century. While technology, increased mobility, industrialization, urbanization and globalization have advanced human, animal and environmental health in many ways, they’ve also made us more vulnerable to new health challenges.

For example, according to the Centers for Disease Control and Prevention, every year, millions of people and animals around the world are affected by zoonotic diseases. Scientists estimate that around 60% of emerging infectious diseases that are reported globally come from animals, both wild and domestic. Over 30 new human pathogens have been detected in the last 3 decades, 75% of which have originated in animals.

They can be spread in a number of ways, including direct or indirect contact, vector-borne, foodborne or waterborne. In fact, foodborne pathogens cause millions of cases of sporadic illness and chronic complications, as well as large and challenging outbreaks in many countries and between countries.

In addition, increased exposure to new viruses/bacteria combined with excessive and/or inappropriate use of medicines is causing a rise in AMR. Worldwide, an estimated 4.95 million people died with drug-resistant bacterial infections in 2019, and 1.27 million of these deaths were directly caused by antimicrobial resistance (AMR).

Three main factors are fueling these population health threats, increasing the probability and speed of spreading diseases. They are:

farmland landscape with livestock

Changes in climate and land use

Deforestation and other disruptions in environmental conditions can provide new opportunities for diseases to develop.

Exponential population growth and expansion into previously uninhabited areas

More people are living in close connection to their companion animals, and in some cases, closer to wild and domestic animals.

world map with lines showing increasing mobility

Increased international mobility

People, animals and animal products are moving more frequently, easily and widely than ever before.

Our commitment to One Health

With deep expertise in both human and animal health and a commitment to our shared environment, our company is well-positioned to be a leader in the One Health approach.

“We recognize the issues — such as zoonotic and infectious diseases and food safety and security — are interrelated,” says Ian Tarpey, Ph.D., VP, biological research and development, Merck Animal Health. “Our Animal Health and Human Health teams will continue to collaborate to discover and develop preventative solutions for existing and emerging diseases in animals and people.”

Our One Health approach focuses on many areas, including:

icon
Disease prevention

We remain focused on discovering and developing vaccines and technologies to help prevent both human and animal diseases.

icon
Surveillance and monitoring

We’re committed to advocating for and participating in scientifically based surveillance monitoring systems to better understand, track and predict health-related issues.

icon
Respecting our environment

We support science-based, environmentally sound international and national programs to address the challenges to environmental health.

icon
Innovation

Our human and animal health research laboratories collaborate in antimicrobial and vaccine research in many ways including sharing enabling technologies, expertise and evaluation of external opportunities. We’re also investing and developing predictive, monitoring and diagnostic technologies to help animal caretakers make data-driven evaluations of an animal’s health status and optimize their animals’ health and well-being.

icon
Stewardship of essential medicines

We’re playing a leading role in addressing AMR by not only discovering and developing medicines and vaccines to treat and prevent infectious diseases in humans and animals but also supporting responsible use of these products.

icon
Safe and sustainable food supply

We continue to work on developing vaccines and other tools to prevent animal disease to ensure a safe, nutritious, sustainable food supply, and we’ve implemented surveillance initiatives to enable more accurate risk profiling, early disease detection and individualized diagnosis/treatment decisions in livestock.

two dogs running on the grass

The science of healthier animals

We build strong partnerships in an effort to improve the health of animals around the world, and approach our work with a deep sense of responsibility — to our customers, consumers, animals, society and the planet.

Our work to promote optimal health continues

“One Health recognizes the interconnectedness of human, animal and environmental health, acknowledging that the well-being of each is intricately linked. By embracing a collaborative approach, we can effectively address the complex challenges and promote optimal health for both humans and animals.”

– Dr. Jenelle Krishnamoorthy, VP, global public policy

Innovation

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

April 11, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

trees with water

Patients inspire us to pursue the best science in our inventions and everything we do. Every innovation has the potential to help build a healthier, more hopeful future for people everywhere — which means taking on some of today’s global health challenges, including Ebola.

Leading the effort to combat Zaire ebolavirus

Our company is a health care leader in the fight against Zaire ebolavirus. Along with external collaborators from all sectors, our scientists are at the forefront of the response to outbreaks of this potentially deadly disease as we continue to help address this global health challenge. Zaire ebolavirus has had a devastating impact on the world and has proved itself to be a potentially deadly and contagious disease, with a survival rate of 50%. While there are six identified Ebola virus species, the Zaire ebolavirus strain has been the leading cause of outbreaks over the last 20 years.

Global public health preparedness against future Zaire ebolavirus outbreaks requires advanced planning, system readiness for rapid deployment and collaboration and partnership between public and private entities around the world. Our partnerships with the World Health Organization (WHO) and other health partners around the globe are a crucial component of our commitment to helping save and improve lives.

“We take Zaire ebolavirus outbreaks very seriously and act with the utmost urgency to support response efforts,” said Paul Scott, clinical director, clinical research vaccines. “Our teams are dedicated to supporting the frontline workers whose brave actions are critical in outbreak response.”

In 2021, we established an agreement with UNICEF to create the world’s first global Ebola Zaire stockpile, the result of breakthrough innovation and collaboration with four leading international health and humanitarian organizations across the world. The global stockpile offers a critical, rapid-response tool.

“It has been our honor to collaborate with WHO, Gavi, UNICEF, the U.S. government and many others in supporting outbreak preparedness and response efforts,” said Andrew (Drew) Otoo, PharmD, president of global vaccines from 2022-2025 and current regional president, Merck. “Through these collaborations, we demonstrate what’s possible when partners come together to pursue a common purpose for patients.”

This level of collaboration continues to be needed for Zaire ebolavirus and other diseases. We remain committed to working in collaboration with global and local health partners to support current and future outbreak response efforts.

Innovation

Harnessing innovative technology in drug discovery

Merck scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading-edge science to save and improve lives

November 16, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Our scientists are leveraging state-of-the-art capabilities to discover novel molecules that may lead to the medicines of tomorrow. 

Merck Research Laboratories (MRL) scientists evaluate hundreds to thousands to up to billions of compounds to find a starting point for a new drug candidate. It all starts with identifying a target — usually a protein — that’s intrinsically associated with a particular disease and can be pharmacologically modulated. That’s where innovative tools like structure-based design, high-throughput screening and high-throughput experimentation, coupled with robotics, artificial intelligence and machine learning can make a huge difference in progressing the work. And once a lead molecule is identified, cryogenic electron microscopy (cryo-EM) as an emerging structural method can be used to understand and improve how a molecule interacts with the protein target.

Utilizing the latest technologies and diligent work by teams of highly skilled and experienced scientists can potentially accelerate the discovery of new medicines for patients in need.

“We have an incredibly creative, smart and hardworking workforce. It’s an absolute pleasure to be part of that and to have access to the resources necessary for making scientific breakthroughs.”

— Adam Weinglass

Executive director in quantitative biosciences
Innovation

Merck’s legacy of antimicrobial innovation and action

Delivering on our commitment to fight infectious diseases for more than a century

October 12, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientist working with liquid

For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to fight infectious diseases. With the growing burden of antimicrobial resistance (AMR), we’ve focused on stopping the increasing threat of AMR

1930s

Merck Research Laboratories played a central role in the development of sulfas, the first synthetic antimicrobial.

vials with background of industrial complex

1940s

In collaboration with Rutgers University, we developed streptomycin, the first antibiotic effective against tuberculosis. We also helped to develop one of the first methods for mass production of penicillin.

scientist taking out trey of vial

1950s & 1960s

We developed multiple novel methods to prevent infectious diseases, including pediatric vaccines.

scientist working with equipment

1970s & 1980s

We received U.S. Food and Drug Administration (FDA) approval for two vaccines, as well as three antibiotics that treat a variety of bacterial infections.

doctor holding patients right arm

1990s & 2000s

Merck received U.S. FDA approval for two antifungals, as well as licenses for two vaccines.​

2002

With resistance to antibiotics developing faster through people, animals and the environment, we launched one of the world’s largest and longest-running antimicrobial resistance surveillance studies. Called the Study for Monitoring Antimicrobial Resistance Trends (SMART), the program enables researchers to monitor and identify trends in the development of AMR.

2010s

We launched an Antimicrobial Stewardship (AMS) Investigator Initiated Studies program, supporting investigator-based, peer-reviewed research supporting the implementation of AMS principles across the globe, with over 20% of studies occurring in low-and middle-income countries.

large building

2016

We created the Merck Exploratory Science Center in Cambridge, Massachusetts, focusing on the earliest stages of research into the underlying biology of human disease.

2016-2017

We supported the first United Nations high-level meeting on AMR and subsequent political declaration in 2016, which set policy action on AMR in motion.

As a next step, we joined the newly founded AMR Industry Alliance – a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help curb antimicrobial resistance.

AMR action fund logo

2020

Merck, along with a group of more than 20 leading biopharmaceutical companies, launched the AMR Action Fund to bring 2-4 new antibiotics to patients by the end of the decade.

2020s

Our staff have championed government actions to create supportive markets for antimicrobial innovation, including the PASTEUR Act in the U.S., inclusion of transferable exclusivity extensions in the EU pharmaceutical strategy, and other incentives around the world.

By collaborating with policymakers, Merck aims to improve appropriate antibiotic use globally.

cow drinking milk from bottle

Going forward

In recognition of our leadership in both human and animal health, Merck represents industry in the One Health Global Leaders Group on Antimicrobial Resistance, which advocates for a One Health approach to help ensure antibiotics remain an important tool in improving and maintaining human and animal health.

Innovation

Podcast: Why neuroscience is the ‘final frontier’

Listen as specialists from Merck discuss what they’re most excited about in researching potential treatments for neurologic disorders

July 11, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Four people in a modern office setting, with two seated on blue chairs and two standing behind them

Our scientists are revolutionizing how we discover and develop treatments to address unmet medical needs in a number of areas, including neuroscience.

“It’s sort of like the final frontier,” said Joe Herring, scientific AVP, clinical research, in our new podcast. “You’re going off into space to try to figure out how to do very difficult things.”

For more, listen in as Herring sits down with Merck clinical research team senior principal scientists Yuki Mukai and Ari Merola as well as business development director Paige Lacatena to explore today’s breakthroughs and challenges in the field of neuroscience.

Listen to the podcast

Read the full transcript

Explore careers in R&D at Merck

Man and women scientists in a lab

Careers

Are you interested in a career in R&D?

Innovation

Individualized neoantigen therapies: exploring one medicine for one patient

Scientists are researching new ways to help train the immune system to fight cancer

April 13, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Over the past decade, immunotherapy has transformed our understanding of how the immune system can be used to help fight some types of cancer. However, for the last 50 years, scientists have been researching how we could potentially use vaccines to treat cancer — another investigational approach to harness the immune system to help recognize and destroy cancer cells — with little success.

Now we’re looking at a potential therapy that is building upon the learnings of immunotherapy trials from the past and incorporating that into an individualized cancer approach that’s specific to a patient’s own tumor. Researchers are currently exploring the potential of individualized neoantigen therapies to help fight cancer.

Cancer research is becoming more personalized

Cancer is a result of the body’s own cells undergoing mutations which create abnormal proteins in cancer cells, known as neoantigens, that are not usually seen in normal cells. These mutations are unique to each person’s tumor, so that’s one of the reasons why patients who have been diagnosed with the same type of cancer and who have received the same type of treatment may have different responses.

As the treatment of cancer continues to evolve and advance, researchers are focusing on more individualized approaches. This includes a new area of research into individualized neoantigen therapies that use information from a person’s tumor biopsy sample to help develop a therapy unique to their tumor’s mutations.

Merck's Dr. Jane Healy

“This area of research has really captured our imagination of what’s possible in the development of cancer therapeutics.”

  • Dr. Jane Healy
    Vice president and head of oncology early development at Merck Research Laboratories

In collaboration with Moderna, we’re studying this area of research in an effort to advance more individualized approaches to help improve outcomes for people living with cancer.

Learn more about individualized neoantigen therapies

infographic of what is an individual neoantigen therapy